Health Discoveries in Colorectal Cancers
Black raspberries may help prevent colorectal cancer
November 4, 2010
Laboratory tests at the University of Illinois at Chicago show black raspberries to have a strong effect in preventing colorectal cancers, according to the November issue of Cancer Prevention Research.
The latest study built on previous research that shows black raspberries are not only antioxidant, but also anti-neurodegenerative and have anti-inflammatory properties.
In tests that compared the effects of a high-fat, low calcium diet and a diet supplemented by freeze-dried black raspberry powder for 12 weeks, the results showed the supplemented diet to offer a range of protective benefits to the intestine, colon and rectum and also inhibited the formation of tumors.
"We saw the black raspberry as a natural product, very powerful, and easy to access," said Dr. Wancai Yang, assistant professor of pathology at the UIC College of Medicine.
According to the National Cancer Institute, colorectal cancer is the third most common cancer in the U.S. and the second leading cause of cancer-related death in men and women.
One of the current clinical trials on colon cancer and rectal cancer within the North Shore-LIJ Health System is examining the effects of chemotherapy with various drug combinations. Patients with either colon or rectal cancer are included in the study.
The latest study built on previous research that shows black raspberries are not only antioxidant, but also anti-neurodegenerative and have anti-inflammatory properties.
In tests that compared the effects of a high-fat, low calcium diet and a diet supplemented by freeze-dried black raspberry powder for 12 weeks, the results showed the supplemented diet to offer a range of protective benefits to the intestine, colon and rectum and also inhibited the formation of tumors.
"We saw the black raspberry as a natural product, very powerful, and easy to access," said Dr. Wancai Yang, assistant professor of pathology at the UIC College of Medicine.
According to the National Cancer Institute, colorectal cancer is the third most common cancer in the U.S. and the second leading cause of cancer-related death in men and women.
One of the current clinical trials on colon cancer and rectal cancer within the North Shore-LIJ Health System is examining the effects of chemotherapy with various drug combinations. Patients with either colon or rectal cancer are included in the study.